Abstract:Objective To investigate the feasibility of breast-conserving therapy(BCT) for locally advanced breast cancer after neoadjuvant chemotherapy(NAC). Methods A total of 31 patients with locally advanced breast cancer underwent breast-conserving therapy after neoadjuvant chemotherapy in this hospital from January 2002 to June 2005.Treatment with neoadjuvant chemotherapy consisted of: ①paclitaxel and epirubicin(TE) regimen-that is,intravenous epirubicin 60 mg/m~2 on day 1 and intravenous paclitaxel 150 mg/m~2 for 3 hours' continuous infusion on day 2;or ②cyclophosphamide,epirubicin,and 5-Fluorouracil(CEF) regimen-that is,intravenous cyclophosphamide 600 mg/m~2 and epirubicin 60 mg/m~2 on day 1,and intravenous 5-fluorouracil 600 mg/m~2 for 4 hours' continuous infusion on day 1.The neoadjuvant chemotherapy was repeated every 21 days,for 3~4 cycles.Outcomes of the neoadjuvant chemotherapy were evaluated using physical examinations,B-ultrasonography,and molybdenum target roentgenography.Patients eligible for breast-conserving therapy were given quadrantectomy or wide excision of tumor plus axillary lymph node dissection.Adjuvant irradiation,chemotherapy and hormone therapy were given postoperatively. Results The overall response rate(ORR) was 90.3%(28/31) for the primary tumor of breast.Eight patients(25.8%) obtained clinical complete response(cCR),including 4 patients(12.9%) with pathological complete response(pCR).Twenty patients(64.5%) achieved clinical partial response(cPR).No progression of disease(PD) was observed.Follow-up for 4~46 months(median,34 months) showed a local recurrence rate of 6.5%(2/31).Distant metastasis to the lung,liver,meninges,and bone occurred in 3 patients(9.7%, 3/31) and 1 of them died.Assessment of cosmetic results was carried out in 25 patients who had received breast-conserving therapy >12 months postoperatively,and excellent results were obtained in 16.0% of the patients((4/25)),good in 40.0%(10/25),and poor in 44.0%(11/25). Conclusions For patients with locally advanced breast cancer previously treated with downstaging neoadjuvant chemotherapy,breast-conserving therapy offers satisfactory results.Strict adherence to technique and use of postoperative irradiation and systemic therapy are crucial to breast-conserving therapy.

CET and CEF Neoadjuvant Chemotherapy Regimen in the Treatment of Breast Cancer

Comparison of Two Different Neoadjuvant Chemoradiatiotherapy Regimens for Locally Advanced Rectal Cancer: Results of a Phase II, Multicenter, Randomized Trial.

Superior Outcome after Neoadjuvant Chemotherapy with Docetaxel, Anthracycline, and Cyclophosphamide Versus Docetaxel Plus Cyclophosphamide: Results from the NATT Trial in Triple Negative or HER2 Positive Breast Cancer

[Efficacy of Adjuvant Endocrine Therapy in Breast Cancer Patients with a Positive-to-negative Switch of Hormone Receptor Status after Neoadjuvant Chemotherapy].

A Multicentric Prospective Study of the Effect of Neoadjuvant Chemotherapy with Cyclophosphamide,Fluorouracil and Pirarubicin on Localy Advanced Breast Cancer

A Single-Center, Randomized, Parallel Controlled Study Comparing the Efficacy and Safety Aspects of Three Anthracycline-Based Regimens As Neoadjuvant Chemotherapy in Primary Breast Cancer

Concurrent Neoadjuvant Chemotherapy and Estrogen Deprivation in Patients with Estrogen Receptor–positive, Human Epidermal Growth Factor Receptor 2–negative Breast Cancer (CBCSG‐036): A Randomized, Controlled, Multicenter Trial

Assessment of neoadjuvant chemotherapy for breast cancer in 40 patients

Relationship Between Tumor Markers, ER/PR, HER2, Ki67 and CyclinA2 and Clinical Efficacy of Neoadjuvant Chemotherapy

The Efficacy of Anthracycline-Based Neoadjuvant Chemotherapy in Patients with Breast Cancer

[Clinical Evaluation of Effects from Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel in Cases of Locally Advanced Breast Cancer--comparative Study of Treatment with 2 and 4 Cycles].

Impact of Adjuvant Chemotherapy on the Survival of Patients with Estrogen Receptor ≥50 ％, Human Epidermal Growth Factor Receptor-2 Negative, Lymph Node Negative Breast Cancer

Clinical observation of neoadjuvant chemotherapy on 86 breast cancer patients

Clinical Evaluation of Neoadjuvant Chemotherapy with Docetaxel for Breast Cancer

Treatment of locally advanced breast cancer with breast-conserving therapy after neoadjuvant chemotherapy: Report of 31 cases

Effect of Local Targeted Chemotherapy in Triple-Negative Breast Cancer

Clinical evaluation of breast conservation operation combining with radiochemotherapy in treating early breast cancer

[A Study of the Combination of Vinorelbine and Epirubicin As Neoadjuvant Chemotherapy Regimen in the Treatment of Locally Advanced Breast Cancer].

Clinical Effect of Breast Conserving Surgery Combined with Neoadjuvant Chemotherapy Treatment for Breast Cancer

Comparison of Therapeutic Efficacy among 3 Different Regimens of Neoadjuvant Chemotherapy for FIGO Stage Ⅰb2-Ⅱb Cervical Squamous Carcinoma Before Operation

Short-term Curative Effects of Docetaxel Combined with Capecitabine in Neoadjuvant Chemotherapy of Triple-negative Breast Cancer and Non Triple-negative Brest Cancer